.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC06_Capecitabine.Capecitabine .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC06_Capecitabine.Capecitabine| name: | Capecitabine |
| ATC code: | L01BC06 | route: | oral |
| n-compartments | 1 |
Capecitabine is an oral prodrug of 5-fluorouracil (5-FU), used as a chemotherapy agent primarily for the treatment of metastatic breast cancer and colorectal cancer. It is approved and widely used in clinical oncology. The drug is enzymatically converted to 5-FU preferentially in tumor tissues.
Pharmacokinetics of capecitabine in adult cancer patients (median age ~56 years, both sexes, solid tumors), following repeated oral administration of 1250 mg/m2 twice daily for 14 days in a 21-day cycle.
Jacobs, BAW, et al., & Huitema, ADR (2019). Pharmacokinetics of Capecitabine and Four Metabolites in a Heterogeneous Population of Cancer Patients: A Comprehensive Analysis. CPT: pharmacometrics & systems pharmacology 8(12) 940–950. DOI:10.1002/psp4.12474 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31652031
Janssen, JM, et al., & Dorlo, TPC (2021). Population Pharmacokinetics of Intracellular 5-Fluorouridine 5'-Triphosphate and its Relationship with Hand-and-Foot Syndrome in Patients Treated with Capecitabine. The AAPS journal 23(1) 23–None. DOI:10.1208/s12248-020-00533-1 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33417061
Li, X, et al., & Zheng, L (2023). Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients. Clinical pharmacology in drug development 12(3) 324–332. DOI:10.1002/cpdd.1202 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36642942